Thermo Fisher Scientific at EACR25
Thermo Fisher Scientific Symposium
The concept that the immune system plays a critical role in anti-tumour responses has been demonstrated and more recently immune checkpoint therapy has started a revolution in the field of oncology research. Several research studies are ongoing to identify appropriate biomarkers and more recently a multi-biomarker approach is seen as the only path to advance immunotherapies research.
See what thoughts leaders have shared during our symposium about their immuno-oncology and liquid biopsy research.
- How new biomarkers like TCR sequencing and mutational burden may enhance immunotherapies studies
- The power of designing your own panels and finding variants with a low limit of detection—down to 0.1% for cell-free DNA samples
Download below what they have presented.